Last reviewed · How we verify

Acute postoperative pain — Treatment Landscape & Competitive Intelligence

Acute postoperative pain (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute postoperative pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Dilaudid-Hp Hydromorphone Hydrochloride Fresenius Kabi Opioid agonist Mu-opioid receptor 1984-01-01
Dilaudid-Hp HYDROMORPHONE Fresenius Kabi Opioid Agonist mu-opioid receptor 1984-01-01
Subutex BUPRENORPHINE Purdue Pharma Lp Partial Opioid Agonist mu-opioid receptor, kappa-opioid receptor 1981-01-01
Subutex Buprenorphine Hydrochloride Indivior partial opioid agonist mu-opioid receptor, kappa-opioid receptor 1981-01-01
Advil ibuprofen Generic (originally Boots Group) Nonsteroidal Anti-inflammatory Drug [EPC] Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2 1969-01-15
Duragesic fentanyl Johnson & Johnson (Janssen Pharmaceutica) Synthetic opioid analgesic D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor 1968-01-01
MS Contin morphine sulfate Generic (multiple manufacturers) Opioid analgesic Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor 1941-01-01
celebrex celebrex POZEN 3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2
Fentanyl (F2) Fentanyl (F2) Oslo University Hospital Synthetic opioid D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Acute postoperative pain
  2. Fresenius Kabi · 2 drugs in Acute postoperative pain
  3. Generic (multiple manufacturers) · 1 drug in Acute postoperative pain
  4. Generic (originally Boots Group) · 1 drug in Acute postoperative pain
  5. Indivior · 1 drug in Acute postoperative pain
  6. Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in Acute postoperative pain
  7. Kocaeli University · 1 drug in Acute postoperative pain
  8. Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in Acute postoperative pain
  9. Oslo University Hospital · 1 drug in Acute postoperative pain
  10. POZEN · 1 drug in Acute postoperative pain
  11. Pfizer · 1 drug in Acute postoperative pain
  12. Pfizer Inc. (originally Searle/Pharmacia) · 1 drug in Acute postoperative pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute postoperative pain:

Cite this brief

Drug Landscape (2026). Acute postoperative pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-postoperative-pain. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing